npj Precision Oncology (Apr 2022)

Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade

  • Seong-Keun Yoo,
  • Diego Chowell,
  • Cristina Valero,
  • Luc G. T. Morris,
  • Timothy A. Chan

DOI
https://doi.org/10.1038/s41698-022-00267-7
Journal volume & issue
Vol. 6, no. 1
pp. 1 – 5

Abstract

Read online

Abstract The effects of cytokine and protein stabilizing carriers, such as serum albumin, on tumor response to immune checkpoint blockade (ICB) is not well understood. By examining 1714 patients across 16 cancer types, we found that high pretreatment serum albumin level predicts favorable tumor radiographic response following ICB treatment in a dose-dependent fashion. Serum albumin is a candidate biomarker that can be combined with tumor mutational burden (TMB) for additional predictive capacity, and the tumor response rate to ICB was ~49% in the albumin-high/TMB-high group.